- Bristol-Myers Squibb Company stock price today and history
Bristol-Myers Squibb Company (BMY) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Bristol-Myers Squibb Company stock price, BMY
Bristol-Myers Squibb Company stock chart:
Bristol-Myers Squibb Company close price: 54.78
Stock price forecast:
UP TO +3.23%
Total forecasts: 63
Reached: 54 (85.71%)
Total Win: 168.09 (297.53%)
Showing 1-10 of 353 items.
|Date of Forecast||Stock Price||Target Price||Forecast Reached Date|
Bristol-Myers Squibb Company latest news:
Icahn buys Bristol-Myers shares, adding to activist pressure
- Billionaire investor Carl Icahn has taken a stake in Bristol-Myers Squibb Co (BMY) and sees the drugmaker as a possible takeover target, according to a report published on Tuesday that sent the company's shares from a loss to more than 2 percent higher.
BRIEF-Bristol-Myers Squibb receives FDA approval for Opdivo (Nivolumab)
* Bristol-Myers Squibb receives FDA approval for Opdivo
(Nivolumab) in previously treated locally advanced or metastatic
urothelial carcinoma, a type of bladder cancer
Bristol-Myers Squibb stock sinks 2.7% after fourth-quarter earnings miss and downbeat outlook
Bristol-Myers Sqibb shares sunk 2.7% in pre-market trade Thursday after the company reported a fourth-quarter earnings miss and revenue beat. Earnings for the latest quarter were $894 million, or 53 cents per share. In the year-earlier period the company had a loss of $197 million, or 12 cents per share. Adjusted EPS was 63 cents, compared with the FactSet consensus of 67 cents. Revenue rose to $5.24 billion from $4.29 billion, beating the FactSet consensus of $5.12 billion. The company said global revenue growth was driven by sales for its blockbuster cancer drug Opdivo, along with drugs Eliquis, Orencia, Sprycel and Yervoy. Bristol-Myers confirmed its 2017 EPS guidance range of $2.47 to $2.67 and reduced its adjusted EPS guidance range to $2.70 to $2.90 from $2.85 to $3.05. Shares of Bristol-Myers have risen 0.5% over the last three months, compared with a 7.4% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Merck will pay $625 million and royalties to settle Keytruda patent litigation with Bristol-Myers Squibb and Ono Pharma
Merck & Co. Inc. will pay $625 million and royalties to Bristol-Myers Squibb Co. and Ono Pharmaceutical Co. Ltd. to settle patent litigation over Merck's cancer drug Keytruda, the companies said Friday afternoon. As part of the settlement all patent litigation will be dismissed, and the companies have granted certain patent rights to each other. Merck will pay royalties on global Keytruda sales of 6.5% between 2017 and the end of 2023 and 2.5% between 2024 and 2026, with the royalties being split 75/25 between Bristol-Myers and Ono. Merck said the $625 million payment would be recorded in its fourth-quarter and full-year 2016 results, but excluded from its non-GAAP results. In their lawsuit against Merck, Bristol-Myers and Ono, which made cancer drug Opdivo, said its Keytruda sales infringed on various of its global patents. Bristol-Myers shares slumped 2.2% over the last three months, compared with a 1.0% rise in Merck shares and a 6.1% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Bristol-Myers shares fall on lung cancer timeline setback
- Shares of Bristol-Myers Squibb (BMY) fell nearly 10 percent on Friday following Thursday's announcement that it would not seek accelerated approval of its immunotherapy drug combination in first-line lung cancer, further solidifying Merck & Co's (MRK) leading position in the burgeoning immuno-oncolgy field.
BRIEF-Bristol-Myers decides not to pursue accelerated regulatory pathway for combination of Opdivo plus Yervoy
* Bristol-Myers Squibb provides regulatory update in
first-line lung cancer
Bristol-Myers Squibb CEO will serve as chairman, too
Bristol-Myers Squibb said Wednesday morning that chief executive officer Giovanni Caforio will also serve as chairman of the Board of Directors, effective May 2. Caforio will take over for Chairman Lamberto Andreotti, who is retiring. Caforio has been CEO since May 2015 and has been a member of the board since 2014. Bristol-Myers Squibb shares rose a scant 0.8% in pre-market trade. Shares have dropped 14.1% year-to-date, compared with a 11.1% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Bristow Group IncBRS
Brixmor Property Group Inc.BRX
Broadridge Financial SolutionsBR
Brookdale Senior Living Inc.BKD
Brookfield Asset Management IncBAM
Brookfield Canada Office PropertiesBOXC
Brookfield DTLA Inc.DTLA^
Brookfield Global Listed Infrastructure Income FunINF
Brookfield High Income Fund Inc.HHY
Brookfield Infrastructure Partners LPBIP